InflaRx (NASDAQ:IFRX) Price Target Cut to $6.00

InflaRx (NASDAQ:IFRX – Get Rating) had its target price reduced by HC Wainwright from $8.00 to $6.00 in a research report released on Thursday, The Fly reports.

A number of other equities research analysts have also recently weighed in on IFRX. Raymond James lifted their price objective on shares of InflaRx from $7.00 to $8.00 and gave the company a strong-buy rating in a research note on Thursday, November 10th. SVB Leerink restated an outperform rating on shares of InflaRx in a report on Wednesday, November 9th.

InflaRx Price Performance

InflaRx stock opened at $2.92 on Thursday. The company has a market cap of $129.08 million, a PE ratio of -3.40 and a beta of 0.97. The company has a fifty day moving average price of $2.60 and a two-hundred day moving average price of $2.34. InflaRx has a 12 month low of $0.78 and a 12 month high of $4.50.

InflaRx (NASDAQ:IFRX – Get Rating) last released its quarterly earnings data on Wednesday, November 9th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.18. Equities research analysts anticipate that InflaRx will post -0.76 earnings per share for the current year.

Institutional Investors Weigh In On InflaRx

Large investors have recently made changes to their positions in the company. Group One Trading L.P. bought a new stake in shares of InflaRx in the 3rd quarter valued at approximately $42,000. Virtu Financial LLC bought a new stake in InflaRx during the first quarter worth approximately $53,000. Marquette Asset Management LLC boosted its position in InflaRx by 136.7% during the second quarter. Marquette Asset Management LLC now owns 78,620 shares of the company’s stock worth $114,000 after purchasing an additional 45,405 shares during the period. Raymond James & Associates boosted its position in InflaRx by 11.1% during the third quarter. Raymond James & Associates now owns 43,423 shares of the company’s stock worth $115,000 after purchasing an additional 4,339 shares during the period. Finally, Raymond James Financial Services Advisors Inc. boosted its position in InflaRx by 55.3% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 148,584 shares of the company’s stock worth $272,000 after purchasing an additional 52,910 shares during the period. Institutional investors own 9.04% of the company’s stock.

About InflaRx

(Get Rating)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.